ToxStrategies, a Philadelphia, PA-based multidisciplinary scientific consulting firm, acquired Modality Solutions, a company that provides biopharmaceutical cold chain for controlled-temperature medical therapies.
The amount of the deal was not disclosed.
The acquisition brings together two consulting firms within the life sciences industry, creating diversification across the customer base.
Founded in 2011 by Gary Hutchinson and Dan Littlefield, Modality optimizes the biopharmaceutical cold chain for novel, fragile, and controlled-temperature medical therapies and provides expert counsel on the complex filing requirements for these advanced drug products. In addition, Modality specializes in shipping validation testing using next generation, multi-modal simulation technologies. Pharmaceutical and biotech clients use its solutions for the development of cold chain operations, as therapies have become more sensitive to changes in temperature. Mr. Hutchison and Mr. Littlefield will continue to lead Modality as a Division of ToxStrategies.
Led by Laurie Couture Haws, President, ToxStrategies is a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences, industrial hygiene and safety, and regulatory compliance. They develop solutions to address the complex scientific, technical, and regulatory challenges confronting their clients, applying sound science and novel approaches tailored to meet the specific needs of any of them, whether a rapid response or a comprehensive analysis is required.
ToxStrategies is a portfolio company of Renovus Capital Partners.
FinSMEs
10/08/2023